Comparative pharmacokinetic study of two lyophilized orally disintegrating tablets formulations of vinpocetine in human volunteers
Keywords:
Bioavailability, Inclusion complex, Lyophilization, Orodispersible tablets, Solid dispersion, VinpocetineAbstract
Vinpocetine is a poorly water soluble drug, commonly used in treatment of various cerebral insufficiency conditions. The aim of this work was to formulate vinpocetine in the form of orally disintegrating tablets (ODTs) and enhance its solubility and dissolution rate. This objective was addressed using lyophilization technique of either solid dispersion using polyethylene glycol 4000 (PEG 4000) or inclusion complex with 2-hydroxypropyl β-cyclodextrin (2HP-β-CD). Differential scanning calorimetry (DSC) and fourier transform-infrared (FT-IR) spectroscopy were used to characterize the solid state of the prepared solid complex. Tablets were prepared by direct compression using 23 factorial design to evaluate the effect of formulation variables (Ac-di-sol concentration 5 or 10%, the ratio of soluble polymer 1:1 or 1:3 and binder type 6% w/w Avicel PH102 or 6% w/w carboxymethyl cellulose) on release characteristics. Results showed that lyophilized ODTs disintegrated within few seconds and had significantly faster dissolution rate (70- 100 % in 5 minutes) compared to the commercial oral tablet (Cavinton®). This was achieved at high content of PEG 4000 or 2 HP-β-CD in presence of 10 % w/w Ac-Di-Sol and 6 % w/w Avicel PH102. The extent of per oral absorption of vinpocetine was determined in healthy human volunteers using randomized crossover design. The relative bioavailability of selected solid dispersion and inclusion complex formulations were found to be 171.98 % and 196.06 % respectively. The study indicated that complexation of vinpocetine with 2-HP-βCD or dispersion in PEG 4000 followed by lyophilization are two successful strategies for enhancing the bioavailability of the drug from ODTs.
References
. Bereczki D, Fekete I. A systematic
review of vinpocetine therapy in acute
ischaemic stroke. Pharmacol. Eur. J.
Clin., 1999(55): p. 349-352.
. Feigin VL, Doronin BM, Popova TF,
Gribatcheva EV, Tchernov DV.
Vinpocetine treatment in acute
ischaemic stoke: a pilot single-blind
randomized. clinical trial. Eur. J.,
(8): p. 81-85.
. Chen JCJ, Tao W, Mei N, Cao S, Jiang
X. Determination of apovincaminic acid
in human plasma by high-performance
liquid chromatography using solid-phase
extraction and ultraviolet detection. J
Chromatogr B., 2006. 830: p. 201ă206.
. Kiss B, Karpati E. Mechanism of action
of vinpocetine. Acta. Pharm. Hung.,
(66): p. 213-214.
. Del Valle, E.M.M., Cyclodextrins and
their uses. a review. Process
Biochemistry, 2004. 39: p. 1033-1046.
. Challa R, Ahuja A, Ali J, Khar RK.
Cyclodextrins in drug delivery: an
updated review. AAPS PharmSciTech ,
Article 34, 2005. 6(2): p. E329-E357.
. Polgar M, Vereczkey, Nyary I.
Pharmacokinetics of vinpocetine and its
metabolite, apovincaminic acid, in
plasma and cerebrospinal fluid after
intravenous infusion. J. Pharm. Biomed.
Anal., 1985. 3: p. 131-139.
. Gupta, S, Srivastav S, Vajpai M. Solid
dispersion technique for improving
solubility of some poorly soluble drugs.
Journal of Pharmacy Research, 2012.
(4): p. 574-1586.
. Ali AA, Ali AMAH. Optimization of
propranolol HCl release kinetics from
press coated sustained release tablets.
Pharmaceutical Development and
Technology, 2012(00): p. 1-9.
. Rudnic E, Schwartz JB , Oral Solid
Dosage forms In: RemingtonÊs
Pharmaceutical Sciences. 18th
edition,1990, Mack publishing Company.
Easton, Pennsylvania, USA. p. 633-
. The Biritich Pharmacopoia. 2001: Vol. I
and Il .London :The statiory office,.
p.705-706,1810-1812
. Kottke MK, Rudnic EM. Tablet Dosage
Forms, in Modern Pharmaceutics, G.S.
Banker, and Rhodes, C.T., Editor. 2002,
Marcel Dekker Inc.: New York. p. 437-
. Alderborn G. Tablets and compaction, in
Pharmaceutics The Science of Dosage
Form Design, M.E. Aulton, Editor. 2002,
Churchill Livingstone: Edinburgh. p. 397-
. Abd Elbary A, Foda N, El-Gazayerly,O,
El Khatib M. Reversed phase liquid
chromatographic determination of
vinpocetine in human plasma and its
pharmacokinetic application. 2002. Anal.
Lett. (35): p. 1041-1054.
. Botha SA, Lötter AP. Compatibility
studies between isosorbide mononitrate
and selected excipients used in the
development of extended release
formulations, . Drug.Dev.Ind.Pharm,
16(4): p. 673.
. Murrell W. Nitroglycerin as a remedy for
angina pectoris. Vol.151. 1879: Lancet.
. Liu L, Zhu S. Preparation and
characterization of inclusion complexes
of prazosin hydrochloride with betacyclodextrin and hydroxypropyl-betacyclodextrin. J Pharm Biomed Anal,
40(1): p. 122-7.
. Ahuja N, Katare O P, Singh B. Studies
on dissolution enhancement and
mathematical modeling of drug release
of a poorly water-soluble drug using
watersoluble carriers. Eur. J. Pharm.
Biopharm, 2007. 65(1): p. 26-38.
. Ribeiro, LSS. Ferreira DC, Veiga FJB.
Physicochemical investigation of the
effects of water-soluble polymers on
vinpocetine complexation with β-
cyclodextirn and its sulfobytyl ether
derivative in solution and solid state. .
Eur. J. Pharm. Sci. , 2003. 20(3): p. 253-
. Jun SW, Kim MS, Kim JS, Park HJ,
Lee S, Woo JS, Hwang SJ. Preparation
and characterization of
simvastatin/hydroxypropyl-β-cyclodextrin
inclusion complex using supercritical
antisolvent (SAS) process. . Eur. J.
Pharm. Biopharm, 2007. 66(3): p. 413-
. Fernandes CM, Teresa VM, Veiga FJ.
Physicochemical characterization and in
vitro dissolution behavior of nicardipinecyclodextrins inclusion compounds. Eur.
J. Pharm. Sci. , 2002. 15(1): p. 79-88.
. Ficarra R. et al. Study of the inclusion
complex of atenolol with betacyclodextrins. J Pharm Biomed Anal,
23(1): p. 231-6.
. Conine JW, Pikal MJ. Pharmacutical
Dosage FormsTablets, ed. H.A.
Liberman, Lachman, L.,Schwartz J.B.
Vol. 1. 1989: New York :Marcel Dekker.
p.329-340.
. Farzana SB, Ibrahim S. Khattab ,
Lyophilized gliclazidepoloxamer solid
dispersions for enhancement of
invitrodissolution and invivo
bioavailability. International Journal of
Pharmacy and Pharmaceutical
Sciences, 2011. 3(2).
. Ribeiroa L, Ferreirab DC, Veiga FJ. In
vitro controlled release of vinpocetinecyclodextrin-tartaric acid
multicomponent complexes from HPMC
swellable tablets. J Control Rel, 2005.
: p. 325-339.
. Jacobsen J, Christrup L, Jensen N.
Medicated chewing gum: pros and cons
Am J Drug Delivery, 2004. 2(2): p. 75-
. Seager H. Drug-delivery products and
the Zydis fast-dissolving dosage form. J
Pharm Pharmacol,, 1998. 50(4): p. 375-
. Loftsson T, Jarho P, Masson M,
Jarvinen T. Cyclodextrins in drug
delivery. Exp. Opinion Drug Del, 2005.
: p. 335-351.
. Senel S, Hincal AA. Drug permeation
enhancement via. buccal route:
Possibilities and limitations. J. Control.
Rel., 2001. 72: p. 133-144.
. Vandecruys R, Peeters J, Verreck G,
Brewster ME. , Use of a screening
method to determine excipients which
optimize the extent and stability of
supersaturated drug solutions and
application of this system to solid
formulation design. Int. J. Pharm., 2007.
(1-2): p. 168-175.
. Yoo SD, Yoon BM, Lee HS, Lee KC.
Increased bioavailability of clomipramine
after sublingual administration in rats. J.
Pharm. Sci. , 1999. 88(11): p. 1119-
. Udata C, Patel J, Pal D, Hejchman E,
Cushman M, Mitra AK. Enhanced
transport of a novel anti-HIV agent--
cosalane and its congeners across
human intestinal epithelial (Caco-2) cell
monolayers. Int. J. Pharm. , 2003.
(1): p. 157-168.
. Martins PS, Ochoa R, Pimenta AM,
Ferreira LA, Melo AL, da Silva JB,
Sinisterra RD, Demicheli C, Frézard F.
Mode of action of beta-cyclodextrin as
an absorption enhancer of the watersoluble drug meglumine antimoniate. Int.
J. Pharm., 2006. 325((1-2)): p. 39-47.
